EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Clinical, pharmacological, and qualitative characterization of drug–drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa

Daniel Kiiza iD, Danial Rostami-Hochaghan, Yussif Alhassan, Kay Seden, Helen Reynolds, Julian P Kaboggoza, Miriam Taegtmeyer, Tao Chen, Elizabeth Challenger, Thokozile Malaba, Duolao Wang, Laura Else und 12 weitere

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae232 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Daniel Kiiza und 23 weiteren Autor:innen. Beteiligte Einrichtung: Research Department, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. Hauptthemen laut MEDLINE: HIV Infections, Drug Interactions, Anti-HIV Agents, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Unitaid, ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We investigated the impact of Drug–Drug Interactions (DDIs) on virologic control among HIV-positive pregnant women initiating antiretroviral therapy while identifying drivers for Traditional Medicine (TM) use and exploring the nature and extent of TM-related DDIs.

Methods

Employing a three-pronged approach, we examined DDIs arising from comedication, including TM, in ART. The DolPHIN-2 trial (NCT03249181) randomized 268 HIV-positive pregnant women in Uganda and South Africa to dolutegravir (DTG)-based (135) or efavirenz-based (133) regimens while systematically recording comedications and screening for DDIs. We used Cox regression models to compare time-to-virologic control between participants with and without DDIs. We conducted in-depth interviews and focus group discussions among 37 and 67 women with and without HIV, respectively, to explore reasons for TM use during pregnancy. Additionally, in-vitro and in-vivo studies evaluated the composition and impact of clay-based TM, mumbwa, on DTG plasma exposure.

Results

The baseline prevalence of DDIs was 67.2%, with TM use prevalent in 34% of participants, with mumbwa being the most frequent (76%, 69/91). There was no difference in virologic response between participants with and without DDIs. Fetal health and cultural norms were among the reasons cited for TM use. Analysis of mumbwa rods confirmed significant amounts of aluminium (8.4%–13.9%) and iron (4%–6%). In Balb-C mice, coadministration of mumbwa led to a reduction in DTG exposure observed in the AUC0-24 (−21%; P = 0.0271) and C24 (−53%; P = 0.0028).

Conclusions

The widespread use of clay-based TM may compromise HIV treatment, necessitating medication screening and counselling to manage DDIs in pregnant women.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsDrug InteractionsAnti-HIV AgentsPregnancy Complications, InfectiousHumansFemalePregnancyAdultUgandaHeterocyclic Compounds, 3-RingSouth AfricaOxazinesAnimalsPyridonesPiperazinesCyclopropanesYoung AdultAlkynesBenzoxazinesMiceDolutegravir

Substanzen

Anti-HIV AgentsHeterocyclic Compounds, 3-RingOxazinesPyridonesPiperazinesCyclopropanesAlkynesBenzoxazinesDolutegravirefavirenz

Autor:innen und Institutionen

  • Research Department, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
  • Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
  • Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK.
  • Division of Epidemiology and Biostatistics, School of Public Health, University of Cape Town, Cape Town, South Africa.
  • Department of Chemistry, University of Liverpool, Liverpool, UK.
  • Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

ORCID-Profile: Daniel Kiiza, Megan Neary, Angela Colbers, Andrew Owen, Saye Khoo

Förderung

  • Unitaid
  • ViiV Healthcare

Zitieren

APA

Kiiza, D., Rostami-Hochaghan, D., Alhassan, Y., Seden, K., Reynolds, H., Kaboggoza, J. P., Taegtmeyer, M., Chen, T., Challenger, E., Malaba, T., Wang, D., Else, L., Hern, F., Sharp, J., Neary, M., Dilly Penchala, S., Waitt, C., Orrell, C., Colbers, A., …, & Lamorde, M. (2024). Clinical, pharmacological, and qualitative characterization of drug–drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae232

Vancouver

Kiiza D, Rostami-Hochaghan D, Alhassan Y, Seden K, Reynolds H, Kaboggoza JP, et al. Clinical, pharmacological, and qualitative characterization of drug–drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae232

BibTeX
@article{Kiiza2024,
  author = {Kiiza, Daniel and Rostami-Hochaghan, Danial and Alhassan, Yussif and Seden, Kay and Reynolds, Helen and Kaboggoza, Julian P and Taegtmeyer, Miriam and Chen, Tao and Challenger, Elizabeth and Malaba, Thokozile and Wang, Duolao and Else, Laura and Hern, Faye and Sharp, Jo and Neary, Megan and Dilly Penchala, Sujan and Waitt, Catriona and Orrell, Catherine and Colbers, Angela and Myer, Landon and Owen, Andrew and Rannard, Steve and Khoo, Saye and Lamorde, Mohammed},
  title = {Clinical, pharmacological, and qualitative characterization of drug–drug interactions in pregnant women initiating HIV therapy in Sub-Saharan Africa},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae232}
}
Kostenlos starten →